Unlocking the Potential of Cell and Gene Therapies: Overcoming Production Challenges

Cell and gene therapies (CGT) are at the forefront of medical innovation, offering hope for diseases once deemed incurable. However, the journey from laboratory breakthroughs to widespread clinical application is fraught with challenges, particularly in scaling up production to meet the soaring demand. A critical aspect of this scale-up is the stringent monitoring for potential contaminants — a task that demands precision, reliability, and adherence to strict timelines.

We cover:

• The susceptibility of CGT research and manufacturing processes to contamination
• The inherent difficulties in detecting Mycoplasma and the innovative methods that simplify its identification
• The current regulatory guidance surrounding Mycoplasma testing and how Droplet Digital PCR (ddPCR) aligns with these standards

Join us to explore how ddPCR technology can streamline your CGT production, ensuring safety, reliability, and cost-effectiveness in bringing groundbreaking therapies to those in need.